זג'ולה 100 מג
medison pharma ltd - niraparib as tosylate monohydrate - קפסולה קשיחה - niraparib as tosylate monohydrate 100 mg - niraparib
קובן
medison pharma ltd - sapropterin dihydrochloride - טבליות מסיסות - sapropterin dihydrochloride 100 mg - sapropterin
קובן
medison pharma ltd - sapropterin dihydrochloride - טבליות מסיסות - sapropterin dihydrochloride 100 mg - sapropterin
קריסויטה 10 מג
medison pharma ltd - burosumab - תמיסה להזרקה - burosumab 10 mg / 1 ml - burosumab
קריסויטה 20 מג
medison pharma ltd - burosumab - תמיסה להזרקה - burosumab 20 mg / 1 ml - burosumab
קריסויטה 30 מג
medison pharma ltd - burosumab - תמיסה להזרקה - burosumab 30 mg / 1 ml - burosumab
ברינורה
medison pharma ltd - cerliponase alfa - תמיסה לאינפוזיה - cerliponase alfa 30 mg / 1 ml - cerliponase alfa
אימסיברי
medison pharma ltd - setmelanotide - תמיסה להזרקה - setmelanotide 10 mg / 1 ml
טייסברי
medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.
פקפנט 100
medison pharma ltd - fentanyl as citrate - ספריי לאף - fentanyl as citrate 1 mg / 1 ml - fentanyl